Swiggy's FY 2020 losses widen 61% to Rs 3,768 crore

Swiggy, however, reported a 115 percent increase in revenue at Rs 2,776, with a total expense of Rs 6,545 crore.

Priyanka Sahay

January 28, 2021 / 11:11 AM IST

Bundl Technologies Pvt Ltd that runs food-delivery service provider Swiggy has reported a loss of Rs 3,768 crore in the financial year 2019-20, a sharp 61 percent increase from Rs 2,345 in the previous year, regulatory filings sourced from business intelligence firm Tofler say.

The revenue for the financial year that ended March 31, 2020, however, increased by 115 percent to Rs 2,776, with a total expense of Rs 6,545 crore.

The Bengaluru-based company's two largest sources of revenue are the delivery fee it charges customers and the commissions it earns from the partner restaurants.

Rival Zomato, which also runs restaurant discovery besides food delivery, earlier this month, reported a loss of Rs 2,451 crore during the period under review against a revenue of Rs 2,486 crore.

The order volumes of the two biggest players in the country's food-delivery space were hit in the calendar year 2020 following the coronavirus outbreak and subsequent lockdown.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show